Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | Phase 1 / Phase 2 | withdrawn | Oct 14, 2009 | Mayo Clinic | not stated | Not stated |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in…(ANCHOR) | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | Oncopeptides AB | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Sponsor / business decision |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction… | Phase 2 | withdrawn | Jan 10, 2020 | Attaya Suvannasankha | lack of funding | Funding |
| NCT05570188 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic… | Phase 1 / Phase 2 | withdrawn | Oct 6, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT05571540 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT05015972 | UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | Early Phase 1 | withdrawn | Aug 23, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer… | N/A | terminated | Oct 22, 2020 | University of Michigan Rogel Cancer Center | accrual difficulties | Enrollment / accrual |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | Phase 1 | terminated | Mar 4, 2021 | Samus Therapeutics, Inc. | Samus Therapeutics Company Closure | Sponsor / business decision |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | Early Phase 1 | withdrawn | Jul 30, 2021 | Weill Medical College of Cornell University | Funding withdrawn | Funding |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to… | Phase 1 / Phase 2 | terminated | Jun 20, 2013 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic… | Phase 1 / Phase 2 | terminated | Aug 15, 2011 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia… | Phase 2 | terminated | May 8, 2018 | M.D. Anderson Cancer Center | Due to Competing Studies | Other (stated, no rule matched) |
| NCT04655261 | Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection…(FIRST) | — | terminated | Dec 7, 2020 | AbbVie | Lack of Recruitment | Enrollment / accrual |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant… | Phase 1 / Phase 2 | terminated | Aug 7, 2020 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Study terminated early due to business decision. | Sponsor / business decision |
| NCT02716805 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell… | Phase 1 | terminated | Mar 23, 2016 | Ludwig Institute for Cancer Research | FDA placed on partial hold due to additional data | Other (stated, no rule matched) |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory… | Phase 1 | withdrawn | Nov 19, 2020 | Yazeed Sawalha | Investigational Drug removed from the market | Other (stated, no rule matched) |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic… | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | Phase 2 | terminated | Aug 24, 2015 | Rush University Medical Center | poor accrual | Enrollment / accrual |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple…(ProxiMMity-1) | Phase 1 | withdrawn | Aug 10, 2021 | Amgen | Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons. | Safety / toxicity |
| NCT02898259 | Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell… | Phase 1 / Phase 2 | terminated | Sep 13, 2016 | Brian Hill | Funding was eliminated. | Funding |
| NCT04746131 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed… | Phase 1 | suspended | Feb 9, 2021 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Due to the product development strategy change, without any safety concerns, we (the sponsor of the… | Safety / toxicity |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | Phase 2 | terminated | Oct 9, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons | Safety / toxicity |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell… | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and… | Phase 1 / Phase 2 | terminated | Dec 20, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03422523 | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or…(ARGO) | Phase 2 | terminated | Feb 5, 2018 | University Hospital Southampton NHS Foundation Trust | Failure to reach pre-specified futility boundary | Efficacy / futility |
| NCT03778073 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | Phase 1 | terminated | Dec 19, 2018 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or…(MT-3724NHL001) | Phase 1 / Phase 2 | terminated | Feb 11, 2015 | Molecular Templates, Inc. | Sponsor decision following clinical hold | Sponsor / business decision |
| NCT03488251 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and… | Phase 2 | terminated | Apr 4, 2018 | Molecular Templates, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell… | Phase 1 / Phase 2 | suspended | Oct 15, 2018 | Northwestern University | Protocol being amended for stats/accrual changes as per PI | Enrollment / accrual |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With… | Phase 2 | withdrawn | Dec 11, 2020 | Academic and Community Cancer Research United | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected… | COVID-19 / pandemic |
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in… | Phase 1 / Phase 2 | terminated | Nov 3, 2011 | Criterium, Inc. | Lack of enrollment | Enrollment / accrual |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without…(UNITY-NHL) | Phase 2 / Phase 3 | terminated | Jun 8, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in… | Phase 2 | terminated | Jul 2, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT00464178 | A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory… | Phase 2 | terminated | Apr 23, 2007 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for…(VZCLLPI0146) | Phase 2 | terminated | Nov 16, 2010 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in… | Phase 3 | withdrawn | Mar 15, 2021 | Incyte Corporation | This study was withdrawn due to a business decision. | Sponsor / business decision |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | Phase 1 / Phase 2 | terminated | Mar 15, 2012 | Swiss Cancer Institute | In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine… | Other (stated, no rule matched) |
| NCT04802031 | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma | Phase 2 | withdrawn | Mar 17, 2021 | Thomas Martin, MD | Low accrual | Enrollment / accrual |
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With… | Phase 2 | withdrawn | Jul 13, 2020 | Memorial Sloan Kettering Cancer Center | PI left institution and study is being transferred. | Investigator |
| NCT05160064 | Long-term Registry of Patients Treated With Loncastuximab Tesirine | — | withdrawn | Dec 16, 2021 | ADC Therapeutics S.A. | Sponsor administrative decision | Other (stated, no rule matched) |
| NCT01982175 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia(CLL004) | Phase 2 | suspended | Nov 13, 2013 | Shanghai Zhangjiang Biotechnology Limited Company | recruiting difficulties | Enrollment / accrual |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple… | Phase 2 | withdrawn | Feb 15, 2019 | Academic and Community Cancer Research United | There are no patients enrolled on this study and all efforts are being discontinued. | Enrollment / accrual |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin… | Phase 1 | withdrawn | Apr 8, 2021 | Narendranath Epperla | PI decision | Other (stated, no rule matched) |
| NCT02374424 | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients(GIOTTO) | Phase 2 | terminated | Feb 27, 2015 | Fondazione Italiana Linfomi - ETS | Interim analysis planned as per protocol didn't provide positive outcome therefore enrollment was… | Efficacy / futility |
| NCT03660072 | Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma | — | withdrawn | Sep 6, 2018 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03752541 | Efficacy and Safety Evaluation of BCMA-UCART | N/A | suspended | Nov 26, 2018 | Bioray Laboratories | decided by the sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jan 5, 2023source: clinicaltrials